What's hot

View all perspectives
      Sun et al. MMF+MTX vs CYC/AZA in Takayasu. Overall response rates week 28 58.1% vs 32.4%, week 52 55.4% vs 32.4%. So MMF

      Richard Conway RichardPAConway

      9 months 3 weeks ago
      Sun et al. MMF+MTX vs CYC/AZA in Takayasu. Overall response rates week 28 58.1% vs 32.4%, week 52 55.4% vs 32.4%. So MMF+MTX>CYC/AZA. But I'm not sure what to do with these results. How does it compare to toc or ada? @RheumNow #ACR24 Abstr#1696 https://t.co/Jr6S2c6AKs https://t.co/L8pMFJ5hnj
      Safer and less relapses in
      #Takayasu’s #arteritis
      In
      #MTX + #MMF
      Vs
      #Cyclo ➡️ #azathioprine

      @RheumNow #ACRBes

      Janet Pope Janetbirdope

      9 months 3 weeks ago
      Safer and less relapses in #Takayasu’s #arteritis In #MTX + #MMF Vs #Cyclo ➡️ #azathioprine @RheumNow #ACRBest @ACRheum abst#1696 WOW 😮 Amazing! https://t.co/y3BDjdAa6P
      Can we use MTX+MMF to treat active #TAK rather than CYC?

      ➡️MTX+MMF vs CYC/AZA over 52W

      MTX+MMF had:
      ⬆️Better e

      Mrinalini Dey DrMiniDey

      9 months 3 weeks ago
      Can we use MTX+MMF to treat active #TAK rather than CYC? ➡️MTX+MMF vs CYC/AZA over 52W MTX+MMF had: ⬆️Better efficacy in inducing & maintaining remission ❕Comparable safety to CYC/AZA ⏩This combination may prove preferable to using CYC Ab1696 #ACR24 @RheumNow https://t.co/S0A8YNk3qL
      A#1691
      Biomarkers for Rx response SSc ILD?
      92 SSc-ILD pts, 19 had progressive pulm fibrosis (PPF)
      KL-6 - incr in PPF, de

      Eric Dein ericdeinmd

      9 months 3 weeks ago
      A#1691 Biomarkers for Rx response SSc ILD? 92 SSc-ILD pts, 19 had progressive pulm fibrosis (PPF) KL-6 - incr in PPF, decr in those w/o PPF CXCL-4 decr across cohort - non-signif trend for more w/o PPF Specifically in MMF: CRP, KL6, CXCL4 are predictive #ACR24 @RheumNow https://t.co/9fG6atcLmK
      #Methotrexate is a dud in #PMR for benefit above #glucocorticoids !

      #RCT MTX25mg/wk + Pred 15
      Mg/d tapered to 0 at 1 yr

      Janet Pope Janetbirdope

      9 months 3 weeks ago
      #Methotrexate is a dud in #PMR for benefit above #glucocorticoids ! #RCT MTX25mg/wk + Pred 15 Mg/d tapered to 0 at 1 yr vs #Prednisone + placebo same taper NO BENEFIT from #MTX #1697 #ACR24 @ACRheum @RheumNow As FYI Poster at #EULAR observed #Leflunomide better than #MTX https://t.co/RepBmOKIsA
      Abstract 1686: Urinary proteomics reveals potential markers (MMP-13, M-CSF receptor, CD163, ALCAM, FOLR2) and pathways (

      Akhil Sood MD AkhilSoodMD

      9 months 3 weeks ago
      Abstract 1686: Urinary proteomics reveals potential markers (MMP-13, M-CSF receptor, CD163, ALCAM, FOLR2) and pathways (neutrophil degranulation, ECM, tissue remodeling) involved in lupus nephritis Class II. @RheumNow #ACR24 https://t.co/kufd2zl9yc
      @kekuchinad A#1689PFT ref equations -> inequities in SSc ILDPredict FVC uses age, ht, sex & race- higher % pr

      Eric Dein ericdeinmd

      9 months 3 weeks ago

      @kekuchinad A#1689 PFT ref equations -> inequities in SSc ILD Predict FVC uses age, ht, sex & race - higher % pred values -> underdx Race-specific v neutral equations: More black pts meet trial eligibility (69/57%), immunos (56/40), lung t, (14/9) @RheumNow #ACR24 #ACRBest https://t.co/40PFmdk3Xv

      Is there a less invasive approach to evaluate lupus nephritis?

      Abstract 1683 highlights the potential role of 68Ga-FAPI

      Akhil Sood MD AkhilSoodMD

      9 months 3 weeks ago
      Is there a less invasive approach to evaluate lupus nephritis? Abstract 1683 highlights the potential role of 68Ga-FAPI PET imaging in evaluating for lupus nephritis. FAPI uptake ↑ in pts with lupus nephritis vs HC. Correlated with IFN -α and IFN-γ pathways. @RheumNow #ACR24
      Very neat simulated model of GC regimens in AAV pt on fixed RTX by @zach_wallace_md and co

      Over 5 years:
      - No differe

      Brian Jaros, MD Dr_Brian_MD

      9 months 3 weeks ago
      Very neat simulated model of GC regimens in AAV pt on fixed RTX by @zach_wallace_md and co Over 5 years: - No difference in relapse btwn standard GC vs. minimal GC + avacopan - Higher DMII rates in standard group Adds to trial + real world data @RheumNow #ACR24 Abst 1598
      Will my patient with lupus nephritis respond well to induction therapy?

      Abstract 1685: Aundhia et al demonstrate the pr

      Akhil Sood MD AkhilSoodMD

      9 months 3 weeks ago
      Will my patient with lupus nephritis respond well to induction therapy? Abstract 1685: Aundhia et al demonstrate the promising utility of RAIL to predict complete renal response in patients with lupus nephritis (Class III or IV +/- V) @RheumNow #ACR24 https://t.co/JBldrrwUhN
      #1689: race-neutral 🫁 function equations in SSc improve equity:

      🔹 Race-specific equations underestimate disease s

      Caoilfhionn Connolly CaoilfhionnMD

      9 months 3 weeks ago
      #1689: race-neutral 🫁 function equations in SSc improve equity: 🔹 Race-specific equations underestimate disease severity in Black patients. 🔹 Switching to race-neutral reclassified 45% of Black patients to more severe, 16% of White patients to less severe @RheumNow #acr24 https://t.co/BfK2PsCMX5
      Belimumab, anifrolumab and voclosporin exhibited an increase in claims from 2017-2022 for #SLE
      Belimumab ~ 600% increase

      Bella Mehta bella_mehta

      9 months 3 weeks ago
      Belimumab, anifrolumab and voclosporin exhibited an increase in claims from 2017-2022 for #SLE Belimumab ~ 600% increase!! @RheumNow #ACR24 abst#1259 https://t.co/norl1xk2KF
      #SLE treatments #ACR24:
      Compared efficacy & safety of belimumab vs. telitacicept (targets B-lymphocyte stimulator (B

      Bella Mehta bella_mehta

      9 months 3 weeks ago
      #SLE treatments #ACR24: Compared efficacy & safety of belimumab vs. telitacicept (targets B-lymphocyte stimulator (BLyS) and proliferation-inducing ligand(APRIL)) Both improved disease activity with no difference in efficacy Belimumab had lower infection rates @RheumNow abst1544
      More data from PAISLEY, deucravacitinib in SLE

      Small but significant benefit w/respect to joints, a little disappointin

      Mike Putman EBRheum

      9 months 3 weeks ago
      More data from PAISLEY, deucravacitinib in SLE Small but significant benefit w/respect to joints, a little disappointing tbh Would like to see this for all manifestations ie pericarditis, pleuritis, etc Anyone have an infographic or useful chart? #ACR20 @RheumNow Abstr#1552 https://t.co/tXUoUtssxo
      Low uptake of SGLT2i in Lupus nephritis
      SGLT2i users had similar adverse event rates as ACEi/ARB users
      SGLT2i users expe

      Bella Mehta bella_mehta

      9 months 3 weeks ago
      Low uptake of SGLT2i in Lupus nephritis SGLT2i users had similar adverse event rates as ACEi/ARB users SGLT2i users experienced more weight loss #ACR24 @rheumnow abst#1534 https://t.co/tB5o7tyhu5
      How well do you know this week's rheumatology news?
      Take the rheumIQ quiz
      Take the RheumIQ Quiz

      Podcasts

      • ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
      • ACR24 JAK TYK Topic Panel
      • RheumNow Day 1 Recap ACR Convergence 2024 Highlights

      Catch up on Conference Podcasts

      ×